Gazyvaro的获批,基于III期CLL11研究的数据。数据表明,与美罗华(MabThera,通用名:rituximab,利妥昔单抗)+苯丁酸氮芥组合疗法相比,Gazyvaro+苯丁酸氮芥组合疗法使疾病恶化或死亡风险显著降低61%,显著延长了患者的疾病无进展生存期(PFS:26.7个月 vs 15.2个月,p<0.001),同时也增加了缓解深度(以微小残留病(MRD)评价: 37.7% vs 3.3%),并取得了较高的完全缓解率( 21% vs 7%)。此外,与与苯丁酸氮芥单药疗法相比,Gazyvaro+苯丁酸氮芥组合疗法也增加了初治CLL患者的总生存期(OS)。
Q3 11: First pt enrolled in the PIII GOYA (BO21005; NCT01287741) study. It will compare obinutuzumab + CHOP vs. rituximab + CHOP in indolent & diffuse large B-cell lymphoma. The primary endpoint will be PFS. Approximately 1,400 patients are expected to be enrolled in the EU (including UK), US, Australia, Canada, Japan, Thailand & Korea [1,2]. 06/03/2012 16:44:52
The annual incidence of DLBCL is 5-6/100,000 (increasing from 0.3/100,000 in those aged 35-39 years to 26.6/100,000 in those aged 80-84 years) [4]. There are around 4,835 new cases of DLBCL per year in the UK, the majority of which are CD20-positive [5]